S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
Ride These Railroad Stocks for Growth and Income
The Next Big Crisis Is Here (Ad)
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Microsoft’s Comeback Is Now Underway
The Next Big Crisis Is Here (Ad)
Can Amazon Recover Amid Tech Stock Sell-off?
KLA Corporation: Strength In A Troubled Semi-Market
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
Ride These Railroad Stocks for Growth and Income
The Next Big Crisis Is Here (Ad)
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Microsoft’s Comeback Is Now Underway
The Next Big Crisis Is Here (Ad)
Can Amazon Recover Amid Tech Stock Sell-off?
KLA Corporation: Strength In A Troubled Semi-Market
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
Ride These Railroad Stocks for Growth and Income
The Next Big Crisis Is Here (Ad)
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Microsoft’s Comeback Is Now Underway
The Next Big Crisis Is Here (Ad)
Can Amazon Recover Amid Tech Stock Sell-off?
KLA Corporation: Strength In A Troubled Semi-Market
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
Ride These Railroad Stocks for Growth and Income
The Next Big Crisis Is Here (Ad)
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Microsoft’s Comeback Is Now Underway
The Next Big Crisis Is Here (Ad)
Can Amazon Recover Amid Tech Stock Sell-off?
KLA Corporation: Strength In A Troubled Semi-Market
NASDAQ:BIAF

bioAffinity Technologies - BIAF Competitors

$2.87
-0.19 (-6.20%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.70
$3.24
50-Day Range
$1.52
$3.06
52-Week Range
$1.31
$15.55
Volume
834,953 shs
Average Volume
4.34 million shs
Market Capitalization
$7.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

BIAF vs. ISPC, ADXS, NVOS, HSTO, AHPI, KRBP, NBY, ENSC, KPRX, and THMO

Should you be buying bioAffinity Technologies stock or one of its competitors? The main competitors of bioAffinity Technologies include iSpecimen (ISPC), Advaxis (ADXS), Novo Integrated Sciences (NVOS), Histogen (HSTO), Allied Healthcare Products (AHPI), Kiromic BioPharma (KRBP), NovaBay Pharmaceuticals (NBY), Ensysce Biosciences (ENSC), Kiora Pharmaceuticals (KPRX), and ThermoGenesis (THMO). These companies are all part of the "medical" sector.

bioAffinity Technologies vs.

iSpecimen (NASDAQ:ISPC) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

iSpecimen received 3 more outperform votes than bioAffinity Technologies when rated by MarketBeat users.

CompanyUnderperformOutperform
iSpecimenOutperform Votes
3
75.00%
Underperform Votes
1
25.00%
bioAffinity TechnologiesN/AN/A

iSpecimen currently has a consensus price target of $7.63, indicating a potential upside of 367.79%. Given iSpecimen's higher probable upside, equities analysts clearly believe iSpecimen is more favorable than bioAffinity Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iSpecimen
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
bioAffinity Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

bioAffinity Technologies has lower revenue, but higher earnings than iSpecimen.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iSpecimen$11.14 million1.28-$8.96 millionN/AN/A
bioAffinity TechnologiesN/AN/A-$6.33 millionN/AN/A

bioAffinity Technologies has a net margin of 0.00% compared to iSpecimen's net margin of -101.49%. bioAffinity Technologies' return on equity of 0.00% beat iSpecimen's return on equity.

Company Net Margins Return on Equity Return on Assets
iSpecimen -101.49% -38.56% -31.84%
bioAffinity Technologies N/A N/A N/A

11.6% of iSpecimen shares are owned by institutional investors. Comparatively, 2.4% of bioAffinity Technologies shares are owned by institutional investors. 32.3% of iSpecimen shares are owned by company insiders. Comparatively, 51.0% of bioAffinity Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, iSpecimen and iSpecimen both had 4 articles in the media. iSpecimen's average media sentiment score of 0.46 beat bioAffinity Technologies' score of 0.13 indicating that iSpecimen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
iSpecimen
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
bioAffinity Technologies
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

iSpecimen beats bioAffinity Technologies on 6 of the 11 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIAF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIAF vs. The Competition

MetricbioAffinity TechnologiesCommercial physical research IndustryMedical SectorNASDAQ Exchange
Market Cap$7.84M$4.28B$4.53B$5.76B
Dividend YieldN/A1.14%2.34%4.04%
P/E RatioN/A12.52154.8413.23
Price / SalesN/A11,843.173,584.2078.26
Price / CashN/A21.0823.38108.77
Price / BookN/A29.916.345.85
Net Income-$6.33M$81.00M$164.89M$242.13M
7 Day Performance88.98%6.33%5.63%5.13%
1 Month Performance67.01%24.40%32.03%25.95%
1 Year PerformanceN/A-25.50%-5.33%-8.44%

bioAffinity Technologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ISPC
iSpecimen
1.8206 of 5 stars
$1.62
flat
$7.63
+369.3%
-61.9%$14.24M$11.14M0.0059Short Interest ↓
ADXS
Advaxis
0 of 5 stars
$2.39
-16.5%
N/AN/A$4.33M$3.24M-0.27N/AAnalyst Report
Gap Down
NVOS
Novo Integrated Sciences
0 of 5 stars
$0.12
+8.8%
N/A-88.8%$4.35M$9.31M-0.2791Gap Up
HSTO
Histogen
2.0607 of 5 stars
$1.02
+4.1%
$30.00
+2,841.5%
-76.7%$4.36M$1.03M-0.2522Short Interest ↑
AHPI
Allied Healthcare Products
0 of 5 stars
$1.07
-0.9%
N/A-81.9%$4.29M$27.05M-0.80189Analyst Report
News Coverage
KRBP
Kiromic BioPharma
0 of 5 stars
$0.28
+33.8%
N/A-78.7%$4.39MN/A-0.2719Positive News
High Trading Volume
NBY
NovaBay Pharmaceuticals
0 of 5 stars
$2.23
+3.7%
$4.00
+79.4%
N/A$4.18M$8.42M-0.40N/A
ENSC
Ensysce Biosciences
2.3549 of 5 stars
$0.71
+4.4%
$8.00
+1,028.3%
-57.6%$4.55M$3.53M-0.044Positive News
Gap Up
KPRX
Kiora Pharmaceuticals
2.3766 of 5 stars
$4.00
+8.4%
$70.00
+1,650.0%
-87.4%$4.57M$10,000.00-0.0714Short Interest ↑
Gap Up
THMO
ThermoGenesis
2.2834 of 5 stars
$3.93
+19.8%
$45.00
+1,045.0%
-89.6%$4.08M$9.29M-0.1339Short Interest ↓
High Trading Volume
This page (NASDAQ:BIAF) was last updated on 1/28/2023 by MarketBeat.com Staff